Published in Psychopharmacology (Berl) on December 22, 2005
N-acetylcysteine (NAC) for Pediatric Obsessive-Compulsive Disorder | NCT01172275
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther (2011) 1.71
A randomized controlled pilot trial of oral N-acetylcysteine in children with autism. Biol Psychiatry (2012) 1.58
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. J Psychiatry Neurosci (2011) 1.35
The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav (2011) 1.29
Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology (2013) 1.08
Neurobiology of obsessive-compulsive disorder: insights into neural circuitry dysfunction through mouse genetics. Curr Opin Neurobiol (2011) 1.07
Targeting glial physiology and glutamate cycling in the treatment of depression. Biochem Pharmacol (2009) 1.07
Effects of ketamine in treatment-refractory obsessive-compulsive disorder. Biol Psychiatry (2012) 1.06
N-acetyl cysteine treatment rescues cognitive deficits induced by mitochondrial dysfunction in G72/G30 transgenic mice. Neuropsychopharmacology (2011) 1.02
Comorbid Obsessive-Compulsive Symptoms in Schizophrenia: Insight into Pathomechanisms Facilitates Treatment. Adv Med (2014) 0.97
Comorbid obsessive-compulsive symptoms in schizophrenia: contributions of pharmacological and genetic factors. Front Pharmacol (2013) 0.97
Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder. Curr Chem Genomics (2008) 0.95
A double-blind, placebo-controlled trial of lamotrigine for pathological skin picking: treatment efficacy and neurocognitive predictors of response. J Clin Psychopharmacol (2010) 0.94
N-acetyl cysteine in the treatment of obsessive compulsive and related disorders: a systematic review. Clin Psychopharmacol Neurosci (2015) 0.90
Molecular strategies for targeting antioxidants to mitochondria: therapeutic implications. Antioxid Redox Signal (2015) 0.89
A selective review of glutamate pharmacological therapy in obsessive-compulsive and related disorders. Psychol Res Behav Manag (2015) 0.89
Immune therapy in autism: historical experience and future directions with immunomodulatory therapy. Neurotherapeutics (2010) 0.88
Rapid resolution of obsessions after an infusion of intravenous ketamine in a patient with treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry (2011) 0.87
Drug treatment of obsessive-compulsive disorder. Dialogues Clin Neurosci (2010) 0.85
Pharmacological treatment of obsessive-compulsive disorder. Psychiatr Clin North Am (2014) 0.84
Neuromodulation for obsessive-compulsive disorder. Neurotherapeutics (2014) 0.83
Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med (2012) 0.83
Glutamate and the Treatment of Obsessive-Compulsive Disorder. Psychopharm Rev (2010) 0.83
Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. J Clin Psychiatry (2010) 0.82
Isoforms of the neuronal glutamate transporter gene, SLC1A1/EAAC1, negatively modulate glutamate uptake: relevance to obsessive-compulsive disorder. Transl Psychiatry (2013) 0.81
LOWER POSTERIOR CINGULATE CORTEX GLUTATHIONE LEVELS IN OBSESSIVE-COMPULSIVE DISORDER. Biol Psychiatry Cogn Neurosci Neuroimaging (2016) 0.80
Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety (2013) 0.77
Novel therapeutic targets in depression and anxiety: antioxidants as a candidate treatment. Curr Neuropharmacol (2014) 0.77
Riluzole augmentation in treatment-refractory obsessive-compulsive disorder: a pilot randomized placebo-controlled trial. J Clin Psychiatry (2015) 0.77
The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders. Curr Psychiatry Rev (2014) 0.77
High-dose glycine treatment of refractory obsessive-compulsive disorder and body dysmorphic disorder in a 5-year period. Neural Plast (2010) 0.76
Glutamate modulators in the treatment of obsessive-compulsive disorder. Psychiatr Ann (2015) 0.75
Management of obsessive-compulsive disorder comorbid with bipolar disorder. Indian J Psychiatry (2017) 0.75
Glutamatergic agents for OCD and related disorders. Curr Treat Options Psychiatry (2015) 0.75
THE USE OF GLUTAMATE MODULATING DRUGS IN OBSESSIVE COMPULSIVE DISORDER. Child Adolesc Psychopharmacol News (2010) 0.75
Protective and therapeutic potency of N-acetyl-cysteine on propionic acid-induced biochemical autistic features in rats. J Neuroinflammation (2013) 0.75
Pathophysiology of refractory obsessive-compulsive disorder: A study of visual search combined with overactive performance monitoring. Medicine (Baltimore) (2017) 0.75
Behavioral responses in rats submitted to chronic administration of branched-chain amino acids. JIMD Rep (2013) 0.75
Efficacy of N-Acetylcysteine Augmentation on Obsessive Compulsive Disorder: A Multicenter Randomized Double Blind Placebo Controlled Clinical Trial. Iran J Psychiatry (2017) 0.75
Neuroadaptations in cystine-glutamate exchange underlie cocaine relapse. Nat Neurosci (2003) 4.63
Cystine/glutamate exchange regulates metabotropic glutamate receptor presynaptic inhibition of excitatory transmission and vulnerability to cocaine seeking. J Neurosci (2005) 3.08
Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron (1989) 3.06
Functional neuroimaging and the neuroanatomy of obsessive-compulsive disorder. Psychiatr Clin North Am (2000) 2.24
Vulnerability of oligodendroglia to glutamate: pharmacology, mechanisms, and prevention. J Neurosci (1993) 1.86
Clinical practice. Obsessive-compulsive disorder. N Engl J Med (2004) 1.70
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry (2005) 1.52
Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking paroxetine. J Am Acad Child Adolesc Psychiatry (2000) 1.44
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43
Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry (2004) 1.41
Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol (2002) 1.39
Association of a glutamate (NMDA) subunit receptor gene (GRIN2B) with obsessive-compulsive disorder: a preliminary study. Psychopharmacology (Berl) (2004) 1.39
Glutamatergic dysfunction in OCD. Neuropsychopharmacology (2005) 1.36
Symptom stability in adult obsessive-compulsive disorder: data from a naturalistic two-year follow-up study. Am J Psychiatry (2002) 1.33
N-acetyl cysteine-induced blockade of cocaine-induced reinstatement. Ann N Y Acad Sci (2003) 1.26
Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg Clin N Am (2003) 1.20
Riluzole augmentation for treatment-resistant depression. Am J Psychiatry (2004) 1.00
Protection against glutamate-induced cytotoxicity in C6 glial cells by thiol antioxidants. Am J Physiol (1997) 0.99
Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology (Berl) (2003) 0.97
Glutamatergic drugs exacerbate symptomatic behavior in a transgenic model of comorbid Tourette's syndrome and obsessive-compulsive disorder. Brain Res (2000) 0.94
Anxiolytic-like activity of the mGLU2/3 receptor agonist LY354740 in the elevated plus maze test is disrupted in metabotropic glutamate receptor 2 and 3 knock-out mice. Psychopharmacology (Berl) (2004) 0.93
Electrical stimulation of the anterior limbs of the internal capsules in patients with severe obsessive-compulsive disorder: anecdotal reports. Neurosurg Clin N Am (2003) 0.91
Neuroscience: deep in thought. Nature (2005) 0.75
Drug-induced hepatotoxicity. N Engl J Med (1996) 0.75
Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry (2004) 6.05
Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46
Social supports and serotonin transporter gene moderate depression in maltreated children. Proc Natl Acad Sci U S A (2004) 4.42
Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry (2008) 4.06
Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry (2006) 3.97
Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry (2004) 3.64
Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med (2011) 3.36
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med (2008) 3.15
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission. Nat Rev Neurosci (2011) 2.82
Meta-analysis of the symptom structure of obsessive-compulsive disorder. Am J Psychiatry (2008) 2.64
A prospective cohort study investigating factors associated with depression during medical internship. Arch Gen Psychiatry (2010) 2.41
The role of default network deactivation in cognition and disease. Trends Cogn Sci (2012) 2.39
A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36
Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. Biol Psychiatry (2005) 2.36
Association between alcoholism and gamma-amino butyric acid alpha2 receptor subtype in a Russian population. Alcohol Clin Exp Res (2005) 2.35
Systematic review: pharmacological and behavioral treatment for trichotillomania. Biol Psychiatry (2007) 2.35
A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy. Biol Psychiatry (2008) 2.17
Individuals family history positive for alcoholism show functional magnetic resonance imaging differences in reward sensitivity that are related to impulsivity factors. Biol Psychiatry (2010) 2.16
Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15
Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry (2012) 2.10
Efficacy of d-cycloserine for enhancing response to cognitive-behavior therapy for panic disorder. Biol Psychiatry (2009) 2.09
Antidepressant-like effects of ceftriaxone in male C57BL/6J mice. Biol Psychiatry (2006) 2.07
Cortical gamma-aminobutyric acid levels across the menstrual cycle in healthy women and those with premenstrual dysphoric disorder: a proton magnetic resonance spectroscopy study. Arch Gen Psychiatry (2002) 2.01
Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry (2002) 1.99
Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism. Am J Psychiatry (2004) 1.96
Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92
Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J Nucl Med (2005) 1.89
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res (2007) 1.86
Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biol Psychiatry (2008) 1.81
Transcranial magnetic stimulation of left temporoparietal cortex and medication-resistant auditory hallucinations. Arch Gen Psychiatry (2003) 1.81
The antidepressant effect of ketamine is not associated with changes in occipital amino acid neurotransmitter content as measured by [(1)H]-MRS. Psychiatry Res (2011) 1.80
Rare nonsynonymous variants in alpha-4 nicotinic acetylcholine receptor gene protect against nicotine dependence. Biol Psychiatry (2011) 1.76
Impairment of working memory maintenance and response in schizophrenia: functional magnetic resonance imaging evidence. Biol Psychiatry (2008) 1.76
Normalizing effects of modafinil on sleep in chronic cocaine users. Am J Psychiatry (2010) 1.73
Abnormal hemodynamics in schizophrenia during an auditory oddball task. Biol Psychiatry (2005) 1.72
Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70
Partitioning the heritability of Tourette syndrome and obsessive compulsive disorder reveals differences in genetic architecture. PLoS Genet (2013) 1.68
Impaired visual cortical plasticity in schizophrenia. Biol Psychiatry (2012) 1.67
Preliminary evidence for medication effects on functional abnormalities in the amygdala and anterior cingulate in bipolar disorder. Psychopharmacology (Berl) (2005) 1.67
Rare ADH variant constellations are specific for alcohol dependence. Alcohol Alcohol (2012) 1.66
Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry (2003) 1.64
Nicotine effects on brain function and functional connectivity in schizophrenia. Biol Psychiatry (2004) 1.64
Global prefrontal and fronto-amygdala dysconnectivity in bipolar I disorder with psychosis history. Biol Psychiatry (2012) 1.62
Ketamine and the potential role for rapid-acting antidepressant medications. Swiss Med Wkly (2007) 1.62
Genetic and environmental predictors of early alcohol use. Biol Psychiatry (2006) 1.60
Extracellular metabolites in the cortex and hippocampus of epileptic patients. Ann Neurol (2005) 1.55
Temporoparietal transcranial magnetic stimulation for auditory hallucinations: safety, efficacy and moderators in a fifty patient sample. Biol Psychiatry (2005) 1.55
Glutamate metabolism in major depressive disorder. Am J Psychiatry (2014) 1.52
Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry (2005) 1.52
Selecting paradigms from cognitive neuroscience for translation into use in clinical trials: proceedings of the third CNTRICS meeting. Schizophr Bull (2008) 1.52
Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry (2006) 1.51
Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans. Schizophr Bull (2012) 1.50
Genome-wide association study of alcohol dependence implicates KIAA0040 on chromosome 1q. Neuropsychopharmacology (2011) 1.50
Striking differences in glucose and lactate levels between brain extracellular fluid and plasma in conscious human subjects: effects of hyperglycemia and hypoglycemia. J Cereb Blood Flow Metab (2002) 1.48
Age, rapid-cycling, and pharmacotherapy effects on ventral prefrontal cortex in bipolar disorder: a cross-sectional study. Biol Psychiatry (2006) 1.47
Preliminary evidence for persistent abnormalities in amygdala volumes in adolescents and young adults with bipolar disorder. Bipolar Disord (2005) 1.47
Beyond monoamines: glutamatergic function in mood disorders. CNS Spectr (2005) 1.46
Sleep, sleep-dependent procedural learning and vigilance in chronic cocaine users: Evidence for occult insomnia. Drug Alcohol Depend (2005) 1.44
Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo. Biol Psychiatry (2010) 1.44
Scopolamine rapidly increases mammalian target of rapamycin complex 1 signaling, synaptogenesis, and antidepressant behavioral responses. Biol Psychiatry (2013) 1.44
Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. NeuroRx (2006) 1.43
Genetic reduction of striatal-enriched tyrosine phosphatase (STEP) reverses cognitive and cellular deficits in an Alzheimer's disease mouse model. Proc Natl Acad Sci U S A (2010) 1.42
Corpus callosum in maltreated children with posttraumatic stress disorder: a diffusion tensor imaging study. Psychiatry Res (2008) 1.42
Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiatry (2007) 1.42
Cerebrospinal fluid corticotropin-releasing factor and perceived early-life stress in depressed patients and healthy control subjects. Neuropsychopharmacology (2004) 1.41
Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med (2014) 1.39
Age and gender correlates of pulling in pediatric trichotillomania. J Am Acad Child Adolesc Psychiatry (2013) 1.37
Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry (2002) 1.35
Clinical studies implementing glutamate neurotransmission in mood disorders. Ann N Y Acad Sci (2003) 1.35
Effects of NMDA receptor antagonists: implications for the pathophysiology of schizophrenia. Arch Gen Psychiatry (2002) 1.34
Probing the pathophysiology of auditory/verbal hallucinations by combining functional magnetic resonance imaging and transcranial magnetic stimulation. Cereb Cortex (2007) 1.34
Glutamatergic model psychoses: prediction error, learning, and inference. Neuropsychopharmacology (2010) 1.34
Sex, GABA, and nicotine: the impact of smoking on cortical GABA levels across the menstrual cycle as measured with proton magnetic resonance spectroscopy. Biol Psychiatry (2005) 1.33
Sex differences in striatal dopamine release in young adults after oral alcohol challenge: a positron emission tomography imaging study with [¹¹C]raclopride. Biol Psychiatry (2010) 1.33
MAOA genotype, maltreatment, and aggressive behavior: the changing impact of genotype at varying levels of trauma. Biol Psychiatry (2008) 1.32
NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia. Proc Natl Acad Sci U S A (2012) 1.32
N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry (2013) 1.32
Brain-derived neurotrophic factor Val66Met polymorphism and antidepressant efficacy of ketamine in depressed patients. Biol Psychiatry (2012) 1.29
Neural synchrony in schizophrenia: from networks to new treatments. Schizophr Bull (2007) 1.28
CREB, memory enhancement and the treatment of memory disorders: promises, pitfalls and prospects. Expert Opin Ther Targets (2003) 1.26
Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia II: developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biol Psychiatry (2011) 1.26
The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets (2007) 1.25
Riluzole in the treatment of mood and anxiety disorders. CNS Drugs (2008) 1.24